{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T05:08:00Z","timestamp":1779253680918,"version":"3.51.4"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Many evidence-informed high-cost therapies for childhood cancer, including targeted drugs, proton beam therapy (PBT), and cellular therapy (CT) are not publicly funded in Canada. This study aimed to identify disparities and barriers to access, and key health policy changes to improve access to high-cost therapies for children.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted an online cross-sectional vignette-based survey among pediatric oncology providers at 16 Canadian pediatric oncology centres. Vignettes explored access to evidence-informed but not universally funded therapies: blinatumomab for low-risk relapse of B-cell acute lymphoblastic leukemia (B-ALL), larotrectinib for TRK-fused soft tissue sarcoma, PBT for unresectable head-and-neck sarcoma, and tisagenlecleucel for first relapse of B-ALL in a patient with Down syndrome. The primary outcome was access to each therapy, defined as the patient's ability to receive the specified therapy; secondary outcomes included time to access, funding sources, and perceived barriers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seventy participants were enrolled from 15 centres, with 68 (response rate\u2009=\u200997%) completing at least one survey question. Most respondents were pediatric medical oncologists (31\/68, 45.6%). Provider-reported access rates were 89% for blinatumomab (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200935), 79% for larotrectinib (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200927), 59.2% for PBT (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200930), and 94% for tisagenlecleucel (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200930). Key barriers to accessing blinatumomab, PBT, and tisagenlecleucel included patient\/family inability to travel, and the economic and psychosocial impact of travel. High cost of larotrectinib was a notable barrier.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Access to evidence-informed cancer therapies for Canadian children remains variable. Universal funding, simplified approval processes, and the establishment of Canadian PBT centres to reduce travel burden, would ensure timely, equitable access to high-cost therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2026.1793250","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:31:52Z","timestamp":1779251512000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Understanding access to novel high-cost cancer therapies across Canada: a national survey of pediatric oncology providers"],"prefix":"10.3389","volume":"14","author":[{"given":"Kriti","family":"Kumar","sequence":"first","affiliation":[{"name":"Division of Haematology\/Oncology, Department of Paediatrics, The Hospital for Sick Children","place":["Toronto, ON, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avram","family":"Denburg","sequence":"additional","affiliation":[{"name":"Division of Haematology\/Oncology, Department of Paediatrics, The Hospital for Sick Children","place":["Toronto, ON, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celine","family":"Cressman","sequence":"additional","affiliation":[{"name":"Child Health Evaluative Sciences, SickKids Research Institute","place":["Toronto, ON, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek S.","family":"Tsang","sequence":"additional","affiliation":[{"name":"Division of Haematology\/Oncology, Department of Paediatrics, The Hospital for Sick Children","place":["Toronto, ON, Canada"]},{"name":"Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network","place":["Toronto, ON, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel","family":"Romanick","sequence":"additional","affiliation":[{"name":"Provincial Pharmacy Services, Alberta Health Services","place":["Edmonton, AB, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myanca","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University","place":["Hamilton, ON, Canada"]},{"name":"Biostatistics Unit, Father Sean O\u2019Sullivan Research Centre, St Joseph\u2019s Healthcare Hamilton","place":["Hamilton, ON, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J.","family":"Gibson","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Pediatrics, McMaster Children\u2019s Hospital","place":["Hamilton, ON, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/ijc.34753","article-title":"Differences in time to patient access to innovative cancer medicines in six European countries","volume":"154","author":"Vancoppenolle","year":"2024","journal-title":"Int J Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1016\/j.clml.2021.06.022","article-title":"Clinical outcomes of patients with newly diagnosed acute lymphoblastic leukemia in a county hospital system","volume":"21","author":"Apostolidou","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B3","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1002\/cncr.30849","article-title":"Socioeconomic factors affect the selection of proton radiation therapy for children","volume":"123","author":"Shen","year":"2017","journal-title":"Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.ijrobp.2018.12.019","article-title":"The insurance approval process for proton radiation therapy: a significant barrier to patient care","volume":"104","author":"Ning","year":"2019","journal-title":"Int J Radiat Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.ijrobp.2018.12.021","article-title":"Insurance approval for proton beam therapy and its impact on delays in treatment","volume":"104","author":"Gupta","year":"2019","journal-title":"Int J Radiat Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"E664","DOI":"10.1503\/cmaj.190008","article-title":"Proton beam therapy for cancer","volume":"191","author":"Tsang","year":"2019","journal-title":"Can Med Assoc J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.ijrobp.2022.12.021","article-title":"Proton therapy in Canada: toward universal access and health equity with a publicly funded facility","volume":"116","author":"Safavi","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B8","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.radonc.2022.10.004","article-title":"Pan-Canadian consensus recommendations for proton beam therapy access in Canada","volume":"176","author":"Mitera","year":"2022","journal-title":"Radiother Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/jnci\/djaa107","article-title":"Poverty and targeted immunotherapy: survival in children\u2019s oncology group clinical trials for high-risk neuroblastoma","volume":"113","author":"Bona","year":"2021","journal-title":"JNCI J Natl Cancer Inst"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1200\/JCO.22.02200","article-title":"Children\u2019s oncology group AALL1331: phase III trial of blinatumomab in children, adolescents, and young adults with low-risk B-cell ALL in first relapse","volume":"41","author":"Hogan","year":"2023","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S1470-2045(18)30119-0","article-title":"Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1\/2 study","volume":"19","author":"Laetsch","year":"2018","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.1182\/blood-2021-153262","article-title":"Tisagenlecleucel therapy is safe and effective for children with down syndrome with ALL in first relapse","volume":"138","author":"Krueger","year":"2021","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1038\/s41375-022-01550-z","article-title":"Tisagenlecleucel in pediatric and young adult patients with down syndrome-associated relapsed\/refractory acute lymphoblastic leukemia","volume":"36","author":"Laetsch","year":"2022","journal-title":"Leukemia"},{"key":"B14","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1503\/cmaj.080372","article-title":"A guide for the design and conduct of self-administered surveys of clinicians","volume":"179","author":"Burns","year":"2008","journal-title":"Can Med Assoc J"},{"key":"B15","year":"2025"},{"key":"B16","year":"2021"},{"key":"B17","year":"2025"},{"key":"B18","year":"2025"},{"key":"B19","volume-title":"Stata SE","year":"2023"},{"key":"B20","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.annonc.2020.12.015","article-title":"Access to essential anticancer medicines for children and adolescents in Europe","volume":"32","author":"Vassal","year":"2021","journal-title":"Ann Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","article-title":"Blinatumomab added to chemotherapy in infant lymphoblastic leukemia","volume":"388","author":"Van Der Sluis","year":"2023","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2411680","article-title":"Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children","volume":"392","author":"Gupta","year":"2025","journal-title":"N Engl J Med"},{"key":"B23","article-title":"Blinatumomab (blincyto)","volume":"5","year":"2025","journal-title":"Can J Health Technol"},{"key":"B24","article-title":"Larotrectinib (vitrakvi)","volume":"1","year":"2021","journal-title":"Can J Health Technol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e7033","DOI":"10.1002\/cam4.7033","article-title":"Access to innovative therapies in pediatric oncology: report of the nationwide experience in Canada","volume":"13","author":"Judd","year":"2024","journal-title":"Cancer Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.3390\/curroncol31030110","article-title":"Impact of systemic delays for patient access to oncology drugs on clinical, economic, and quality of life outcomes in Canada: a call to action","volume":"31","author":"Sehdev","year":"2024","journal-title":"Curr Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1001\/jamaoncol.2019.4889","article-title":"Comparative effectiveness of proton vs photon therapy as part of concurrent chemoradiotherapy for locally advanced cancer","volume":"6","author":"Baumann","year":"2020","journal-title":"JAMA Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1133909","DOI":"10.3389\/fonc.2023.1133909","article-title":"Proton versus photon radiation therapy: a clinical review","volume":"13","author":"Chen","year":"2023","journal-title":"Front Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/pon.3113","article-title":"Socioeconomic disparities in the quality of life in children with cancer or brain tumors: the mediating role of family factors","volume":"22","author":"Litzelman","year":"2013","journal-title":"Psychooncology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1080\/07347332.2021.2015646","article-title":"The impact of caregiver anxiety\/depression symptoms and family functioning on child quality of life during pediatric cancer treatment: from diagnosis to 6 months","volume":"40","author":"Desjardins","year":"2022","journal-title":"J Psychosoc Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/MPH.0000000000002095","article-title":"Examining the effect of travel distance to pediatric cancer centers and rurality on survival and treatment experiences: a systematic review","volume":"43","author":"Tarnasky","year":"2021","journal-title":"J Pediatr Hematol Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1001\/jamaoncol.2020.2259","article-title":"Race disparities in proton radiotherapy use for cancer treatment in patients enrolled in children\u2019s oncology group trials","volume":"6","author":"Bitterman","year":"2020","journal-title":"JAMA Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"103868","DOI":"10.1016\/j.clon.2025.103868","article-title":"The national referral service for proton beam therapy in England: a journey towards equitable access","volume":"44","author":"Gaito","year":"2025","journal-title":"Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1177\/1049732319889354","article-title":"\u201cEverything is perfect, and we have no problems\u201d: detecting and limiting social desirability bias in qualitative research","volume":"30","author":"Bergen","year":"2020","journal-title":"Qual Health Res"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1793250\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:32:10Z","timestamp":1779251530000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1793250\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":34,"alternative-id":["10.3389\/fped.2026.1793250"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1793250","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"article-number":"1793250"}}